Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study

被引：0
|
作者：
Nuggehally R. Srinivas
机构：
[1] Zydus Research Centre,
[2] a Division of Cadila Healthcare Ltd,undefined
[3] Jubilant Life Sciences,undefined
[4] Innovation and Technology,undefined
来源：
Clinical Drug Investigation | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 107
页数：2
相关论文
共 50 条
  • [41] A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults
    Davies, Rupert
    Peng, Stanford L.
    Lickliter, Jason
    Mclendon, Kristi
    Enstrom, Amanda
    Chunyk, Allison G.
    Blanchfield, Lori
    Wang, Ningxin
    Blair, Tiffany
    Thomas, Heather M.
    Smith, Alina
    Dillon, Stacey R.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (11):
  • [42] First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor
    Shimizu, Hidetoshi
    Tortorici, Michael A.
    Ohta, Yoshiyasu
    Ogawa, Kei
    Rahman, Sheikh Mohammed Ashfaq
    Fujii, Aya
    Hiraga, Yuki
    Kawai, Mizue
    Sugimoto-Kawabata, Kanami
    van Iersel, Mattheus
    van Lier, Jan Jaap
    Djedjos, Stephen
    Slingsby, B. T.
    Rodman, David M.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (08):
  • [43] First-in-Human Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of DISC-0974, an Anti-Hemojuvelin Antibody, in Healthy Participants
    Novikov, Natasha
    Buch, Akshay
    Yang, Hua
    Andruk, Michelle
    Liu, Guowen
    Wu, Min
    Howell, Haley
    Macdonald, Brian
    Savage, Will
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (08): : 953 - 962
  • [44] ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study
    Beale, Dominic
    Dennison, Jeremy
    Boyce, Malcolm
    Mazzo, Francesca
    Honda, Naoki
    Smith, Paul
    Bruce, Mark
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (08) : 3177 - 3189
  • [45] The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects
    Nakahara, Norie
    Wakamatsu, Akira
    Kempsford, Rodger
    Allen, Ann
    Yamada, Masanori
    Nohda, Shigeru
    Hirama, Toshiyasu
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (08) : 660 - 671
  • [46] Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects
    Nomoto, Maiko
    Pastino, Gina
    Rege, Bhaskar
    Aluri, Jagadeesh
    Ferry, Jim
    Han, David
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (02): : 188 - 195
  • [47] Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects
    Tsuda, Yasuhiro
    Grimaldi, Christine
    Huang, Fenglei
    Benediktus, Ewald
    Yagi, Nobutaka
    Padula, Steven J.
    Jang, In-Jin
    Steffgen, Jurgen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (04) : 2000 - 2013
  • [48] A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
    Susanne Johansson
    David P. Rosenbaum
    Mikael Knutsson
    Maria Leonsson-Zachrisson
    Clinical and Experimental Nephrology, 2017, 21 : 407 - 416
  • [49] A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
    Johansson, Susanne
    Rosenbaum, David P.
    Knutsson, Mikael
    Leonsson-Zachrisson, Maria
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (03) : 407 - 416
  • [50] First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and - Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects
    Van Hoogdalem, Ewoud-Jan
    Peeters-Scholte, Cacha M. P. C. D.
    Leufkens, Paul W. T. J.
    Hartstra, Jan
    van Lier, Jan J.
    de Leede, Leo G. J.
    CURRENT CLINICAL PHARMACOLOGY, 2020, 15 (02): : 152 - 163
12345